High Concentrations of Soluble Tumor Necrosis Factor Receptors in Ascites

Andus, Tilo; Groß, Volker; Holstege, Axel; Ott, M.; Weber, Moritz; David, Martina; Gallati, H.; Gerok, W.; Schölmerich, Jürgen

doi:10.1002/hep.1840160322

Cited by 56 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interleukin-6 has been found to be produced in high amounts in the peritoneal cavity of patients with hepatic or malignant ascites. 22 High concentrations of soluble TNF receptors have been found in ascites 22 and may explain why, in recent studies, malignant ascites responded to bolus intraperitoneal injections of TNF. 23 Administration of interferon-alpha 2b also has been shown to reduce ascites.…”

Section: Figmentioning

confidence: 98%

Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

et al. 1999

View full text Add to dashboard Cite

show abstract

Section: Figmentioning

confidence: 98%

Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

et al. 1999

View full text Add to dashboard Cite

show abstract

“…It has been reported that physiologic inhibitors for TNF are present in a variety of body fluids including serum [1,24], urine [23,24], ascites [2], and also in the epithelial lining fluids of the respiratory tract [31]. These inhibitors are soluble TNF receptors (sTNF-Rs) that were cleaved from the extracellular domain of membrane sTNF-Rs.…”

Section: Introductionmentioning

confidence: 99%

Elevated Levels of Type II Soluble Tumor Necrosis Factor Receptors in the Bronchoalveolar Lavage Fluids of Patients with Sarcoidosis

Hino

Nakamura

Shibata

et al. 1997

Lung

View full text Add to dashboard Cite

Since tumor necrosis factor (TNF) is known to be involved in granuloma formation in sarcoidosis, and soluble TNF receptors (sTNF-Rs) inhibit TNF action in vivo, we evaluated the levels of sTNF-Rs in the bronchoalveolar lavage fluids (BALF) of 31 subjects using an enzyme-linked immunosorbent assay. Our group consisted of 13 patients with sarcoidosis (7 sarcoidosis patients who received no treatment and 6 who received corticosteroid therapy) and 18 control subjects (11 healthy nonsmokers and 7 asymptomatic smokers). Type II (75-kDa), but not type I (55 kDa) sTNF-R in BALF was elevated significantly in patients with sarcoidosis compared with the healthy nonsmokers (type I: 126.7 +/- 17.6 pg/ml BALF vs 79.4 +/- 16.5 pg/ml BALF, p > 0.05; type II: 98.3 +/- 27.8 pg/ml BALF vs 26.7 +/- 4.9 pg/ml BALF, p < 0.05). Although levels of type I sTNF-R in BALF from sarcoidosis patients were not correlated with any cellular profiles of BALF, concentrations of type II correlated significantly with the numbers of lymphocytes in BALF. We concluded that sTNF-R is a normal constituent of the epithelial lining fluids and that levels of type II sTNF-R are elevated significantly in the BALF from individuals with sarcoidosis. This suggests that sTNF-Rs may influence the local bioactivity of TNF and may also contribute to the pathogenesis of sarcoidosis.

show abstract

“…Minn., USA). The sTNFRs were determined with an enzyme-linked immunological and biologi cal binding assay (EL1BA) as reported by Andus et al [25], Briefly, samples or sTNFRs standards and recombinant human TNF-a labeled with peroxidase were added to the well of a microtiter plate precoated with non-neutralising monoclonal (mouse) antibodies to sTNFRs (clone htr 20 for the sTNFR-B and clone utr 4 for the sTNFR-A). After incubation for 16-24 h at I5-25°C and a washing step, the peroxidase bound to the microtiter plate was measured enzymatically.…”

Section: Blood Collection and Monocyte Preparationmentioning

confidence: 99%

Effect of 1α-Hydroxyvitamin D<sub>3</sub> Treatment on Production of Tumor Necrosis Factor-α by Peripheral Blood Mononuclear Cells and on Serum Concentrations of Soluble Tumor Necrosis Factor Receptors in Hemodialysis Patients

Haran

Gurwicz²,

Gallati³

et al. 1994

Nephron

View full text Add to dashboard Cite

The effect of 1,25-dihydroxyvitamin D₃ [1,25-(OH)₂D₃] deficiency, as well as of replacement therapy with lα-hydroxyvitamin D₃ [1α-(OH)D₃], on the production of tumor necrosis factor-α (TNF-α) by peripheral blood mononuclear cells (PBMC) and on the serum levels of soluble TNF receptors (sTNFRs) in hemodialysis (HD) patients was investigated. PBMC from HD patients without prior therapy with hydroxylated vitamin D₃ analogs and from normal controls produced similar amounts of TNF-α, either spontaneously or after stimulation with lipopolysaccharide (LPS). After oral administration of 1α-(OH)D₃, a precursor of 1,25-(OH)₂D₃, LPS-induced TNF-α production by PBMC of HD patients was significantly higher than that of HD patients prior to the treatment or of healthy controls. Such treatment did not, however, affect spontaneous TNF-α production by PBMC. Serum concentrations of both soluble TNF receptors [sTNFR-A(p75) and sTNFR-B(p55)] were significantly higher in HD patients than in controls. The ratio of sTNFR-A/sTNFR-B decreased significantly in HD patients following lα-(OH)D₃ therapy. These results suggest that therapy with 1α-hydroxylated vitamin D₃ analogs normally given to HD patients for the management of renal osteodystrophy may also regulate the in vivo activity of TNF-α.

show abstract

High Concentrations of Soluble Tumor Necrosis Factor Receptors in Ascites

Cited by 56 publications

References 40 publications

Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

Elevated Levels of Type II Soluble Tumor Necrosis Factor Receptors in the Bronchoalveolar Lavage Fluids of Patients with Sarcoidosis

Effect of 1α-Hydroxyvitamin D<sub>3</sub> Treatment on Production of Tumor Necrosis Factor-α by Peripheral Blood Mononuclear Cells and on Serum Concentrations of Soluble Tumor Necrosis Factor Receptors in Hemodialysis Patients

Contact Info

Product

Resources

About